Medidata Partnership And AI Launch Will Expand Global Reach

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 Feb 25

Updated

25 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

122.8%

7D

-1.6%

Loading

1Y

122.8%

7D

-1.6%

You can edit this narrative until Nov 26 2:10 PM. Then, changes will post as Updates.

Author's Valuation

AU$3.323.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 25 Nov 25

CGS: Share Buyback Completion Will Support Higher Profit Margins Ahead

Analysts have maintained their price target for Cogstate at $3.30, citing steady profit margin expectations and only minor adjustments to forecasted discount rate, future P/E, and revenue growth assumptions. Valuation Changes Fair Value estimate remains unchanged at A$3.30 per share.

Shared on 10 Nov 25

Fair value Increased 51%

CGS: Share Buyback Completion Will Support Higher Profit Margins Ahead

Analysts have raised their price target for Cogstate from $2.19 to $3.30. They cite improved revenue growth and profit margin forecasts as key drivers of this upward revision.

Shared on 22 Aug 25

Fair value Increased 18%

Upward revisions to Cogstate's revenue growth forecasts and a higher future P/E multiple have driven the consensus analyst price target up from A$1.85 to A$2.19. What's in the News Hosted an Analyst/Investor Day event.

Shared on 01 May 25

Fair value Increased 26%

Shared on 23 Apr 25

Fair value Increased 1.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 2.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 8.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 0.66%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 1.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Decreased 19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

AU$3.3

23.0% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

13.15%

Healthtech revenue growth rate

10.86%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.81%

Calculation

US$16.49m

Earnings '28

x

25.92x

PE Ratio '28

=

US$427.44m

Market Cap '28

US$427.44m

Market Cap '28

/

160.26m

No. shares '28

=

US$2.67

Share Price '28

US$2.67 Share Price '28

Discounted to 2025 @ 7.77% p.a.

=

US$2.13

Fair Value '25

US$2.13 Fair Value '25

Converted to AUD @ 1.5460 USD/AUD Exchange Rate

=

AU$3.29

Fair Value '25